Results 231 to 240 of about 121,621 (353)

Experimental Parkinsonism induced by tetanus toxin injected into basal ganglia

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Local inhibitory circuits and long‐range inhibitory projections within the interconnected basal ganglia nuclei are critical for control of voluntary movement and pathophysiology of different extrapyramidal movement disorders.
Patrik Meglić   +6 more
wiley   +1 more source

An Investigation of Corticospinal Tract Microstructural Integrity in ARSACS Using a Profilometry MRI Analysis: Results From the PROSPAX Study. [PDF]

open access: yesEur J Neurol
Scaravilli A   +17 more
europepmc   +1 more source

T cells from newly diagnosed multiple sclerosis patients have enhanced responsiveness to CD46 activation

open access: yesClinical and Experimental Neuroimmunology, EarlyView.
Abstract Objective To evaluate the responsiveness of T cells from newly diagnosed multiple sclerosis (MS) patients to CD46 co‐stimulation, a membrane co‐factor protein potentially involved in MS pathogenesis. Methods T cells from MS patients and non‐diseased symptomatic controls (SC) were activated in vitro with or without αCD46 antibody co‐stimulation.
Linda Sundvall   +6 more
wiley   +1 more source

TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration

open access: yesProceedings of the National Academy of Sciences of the United States of America, 2010
H. Wils   +9 more
semanticscholar   +1 more source

Reversible spastic paraparesis

open access: yesAnnals of Indian Academy of Neurology, 2019
Indar Kumar Sharawat   +4 more
openaire   +3 more sources

Never Late: Cerebrotendinous Xanthomatosis and Improvements in Neurocognitive Functions in an Adult Patient on Chenodeoxycholic Acid Treatment

open access: yesClinical Genetics, EarlyView.
Cerebrotendinous xanthomatosis is due to biallelic pathogenic variants in CYP27A1. We report a new patient and his good neurocognitive outcome on the chenodeoxycholic acid treatment despite therapy starting at the age of 34 years. This highlights the importance of recognizing treatable inherited metabolic diseases at any age.
Randa Sultan   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy